Head-to-head · WeighScore
ARSYNL Rx vs Nucific
The verdict
ARSYNL Rx takes it — 59.1/100 to 56.2/100.
ARSYNL Rx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. ARSYNL Rx is a veteran-founded multi-service telehealth platform offering compounded GLP-1 weight-loss treatment — compounded semaglutide and tirzepatide, including a needle-free tirzepatide hypospray —…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | ARSYNL Rx | Nucific |
|---|---|---|
| WeighScore | 59.1/100 | 56.2/100 |
| Grade | C | C |
| Scorecard rank | #350 | #417 |
| Semaglutide | $233/mo (compounded) | Not disclosed |
| Tirzepatide | $366/mo (compounded) | Not disclosed |
| Coverage | Coverage not published | Coverage not published |
| Brand-name access | Compounded only | Yes |
| Oral / sublingual | Injection only | Injection only |
Graded #350 · C
Strengths
- Offers compounded semaglutide and tirzepatide, including a needle-free tirzepatide hypospray option
- Veteran-founded telehealth with clinician-prescribed, personalized treatment
- Multi-service platform — also covers hair restoration, TRT, sexual health, and longevity
- Medications shipped discreetly to your home
Where it loses points
- Pricing is not shown until you select a product (product pages sit behind a bot-verification gate)
- Compounded GLP-1s are not FDA-approved finished products
- Compounding pharmacy partner and exact state coverage are not disclosed on the site
- No LegitScript certification visible on the accessible pages
Graded #417 · C
Strengths
- Founder is named and credentialed: Dr. Amy Lee, MD, triple board-certified in Internal Medicine, Obesity Medicine and Clinical Nutrition
- Cites SURMOUNT-1 properly, naming the trial, the 20.9% average and the Jastreboff NEJM 2022 source
- Discloses that featured patients were compensated for their time
- Labels its NAD+ decline chart as illustrative and not a measurement, with an unusually careful methodology note
- Offers compounded, microdosed and brand-name Ozempic and Zepbound in one catalogue
Where it loses points
- No price is published anywhere; every option is gated behind a three-minute quiz
- The LegitScript badge is a self-hosted image with generic alt text rather than the issued embed, so the certification could not be verified
- A BBB Accredited A+ claim is displayed without a link to the BBB profile
- No state list and no named pharmacy, only licensed U.S. pharmacies
- Before-and-after photographs are used alongside compensated testimonials
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.